Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00800540 · ClinicalTrials.gov registry record · Phase 4

Circadian Ocular Perfusion Pressure and Ocular Blood Flow

A Phase 4 study, sponsored by Alcon Research.

Completed
Registry status
Phase 4
Development phase
35
Enrollment target

NCT00800540 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 35 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00800540, a Phase 4 study, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
Phase 4
Development phase
35 participants
Enrollment target

Study Summary

The purpose of this study was to compare the short term effects of two intraocular pressure (IOP) lowering medications on ocular perfusion pressure (OPP), ocular blood flow, intraocular pressure, and blood pressure in patients with glaucoma. Ocular perfusion pressure (OPP) is defined as the difference between arterial blood pressure (diastolic and systolic) and intraocular pressure. The primary efficacy assessment is based on diastolic ocular perfusion pressure.

Interventions

  • DRUG Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension
  • DRUG Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2009-02
Est. Completion 2012-01
Phase Phase 4

Sponsor

Alcon Research

275 total trials

What the Registry Record Tells You About NCT00800540

The ClinicalTrials.gov registry entry for NCT00800540 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension is the first listed.

NCT00800540 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00800540 about?

NCT00800540 is a clinical study titled "Circadian Ocular Perfusion Pressure and Ocular Blood Flow". The purpose of this study was to compare the short term effects of two intraocular pressure (IOP) lowering medications on ocular perfusion pressure (OPP), ocular blood flow, intraocular pressure, and blood pressure in patients with glaucoma. Ocular perfusion pressure (OPP) is defined as the differen...

What is the current status of trial NCT00800540?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2009-02. Estimated completion is 2012-01.

What interventions are being tested in trial NCT00800540?

The interventions under investigation include: Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension (DRUG), Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution (DRUG).

Who is sponsoring clinical trial NCT00800540?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.